Microbiosci Develops Microbial Cell Line Generation for Therapeutics and Diagnostic Applications

Microbiosci, the division of Creative Biogene, is a US-based biotechnology provider dedicated to developing and commercializing recombinant proteins, antibodies, and engineered cell lines through the integration of bioinformatics, and molecular biology. Microbiosci possesses a mature fermentation platform consisting of large fermentation tanks, bioreactors, and large-scale purification systems, which enables the team to provide high-purity and kilogram level products. Recently, Microbiosci announced the release of its microbial cell line generation services in therapeutics, diagnostic, and research applications.

 

Microbiosci's cell line development laboratory is able to generate unparalleled cell lines resulting in Research Cell Bank (RCB) Master Cell Bank (MCB) and Working Cell Bank (WCB), IND and BLA compliant. In addition, GMP-grade cell banks are available for industrial applications. Proper cell line characterization is essential to confirm the certainty of a contamination-free cell bank. Perform cell line characterization on master cell bank (MCB), working cell bank (WCB), and end-of-production cells (EPC) or in vitro cell age-limited (CAL) cells for production. The laboratory of Microbiosci provides proven methods for the characterization of microbial cell lines.

 

Bacterial cell lines: Escherichia coli; Bacillus, Lactococcus lactis, etc.

Yeast cell lines: Saccharomyces cerevisiae, Pichia pastoris, Hansenula polymorpha, etc.

Filamentous fungi: Aspergillus, Trichoderma, etc.

Unicellular algae

 

Microbiosci scales the production of difficult-to-express proteins in a cGMP environment and meets diagnostic product requirements in a robust, reproducible and cost-effective manner, developing and delivering a wide range of reagents for biological research. 

 

Microbiosci has extensive experience in recombinant protein drug process development and large-scale production. The team can perform high-density cultures of engineered microorganisms such as Escherichia coli and Pichia pastoris to obtain high yields of target proteins. Large-scale fermentation equipment and downstream purification systems can undertake 100g-level commissioned production projects. In addition, Microbiosci can also provide customers with GMP-compliant animal safety evaluation samples, pilot samples for clinical applications, as well as sample production and support services for clinical phase I/II pipelines.

 

Microbiosci offers a variety of cell bank characterization services to test the identity, purity and genetic stability of microbial cell banks. Services are provided at research grade, or under GLP or GMP regulations. With the rapid development of genomics, transcriptomics, proteomics and metabolomics, the industrial application of microbial systems offers great potential to heal and feed the world. As a premier research aid, Creative Biogene has extensive experience in characterization of microbial cell banks for pharmaceutical products, pesticides, veterinary drugs and industrial enzymes, as well as providing yeast cell bank characterization services and E. coli cell bank characterization services.

 

“We provide state-of-the-art facilities, capabilities and expertise to accelerate the development, demonstration and commercialization of microbial technologies.” said Marcia Brady, the marketing director of Creative Biogene, she also added, We are capable to provide comprehensive microbial services to support research, process development with fully customizable and flexible methods to satisfy diverse requirements.

 

About Microbiosci

Microbiosci, as the division of Creative Biogene, is always dedicated to satisfying the needs of clients covering more than 50 countries and districts. As a leading custom service provider in delivering medicine microbiology solutions, Microbiosci has become a well-recognized industry leader with years of experience and professional scientists.